Výsledky vyhledávání - "Martin Šmakal"

Akademický článek

Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial

Autor: Ulka Vaishampayan, Patrick Schöffski, Alain Ravaud, Christian Borel, Julio Peguero, Jorge Chaves, John C. Morris, Nuria Kotecki, Martin Smakal, Dongli Zhou, Silke Guenther, Marcis Bajars, James L. Gulley

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-9 (2019)

Abstract Background Antibodies targeting programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) have shown clinical activity in the treatment of metastatic renal cell carcinoma (mRCC). This phase Ib cohort of the JAVELIN Solid Tumor trial ass

Externí odkaz: https://doaj.org/article/f6a78bbebff642488c3eedc3f6c9cbae

Zobrazit plný text záznamu

Akademický článek

Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy

Autor: Zsuzsanna Kahan, Daniela Grecea, Martin Smakal, Sergei Tjulandin, Igor Bondarenko, Luca Perjesi, Andras Illes, Karoly Horvat-Karajz, Ildiko Aradi

Publikováno v: BMC Cancer, Vol 19, Iss 1, Pp 1-10 (2019)

Abstract Background Treatment with recombinant human granulocyte-colony stimulating factor (G-CSF) is accepted standard for prevention of chemotherapy-induced neutropenia. RGB-02 (Gedeon Richter) is a proposed biosimilar to pegylated G-CSF (Neulasta�

Externí odkaz: https://doaj.org/article/b249d2754cfd438da7b013d32c4d7e50

Zobrazit plný text záznamu

Plný text ve formátu HTML

A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC

Autor: Sergey Orlov, Kaoru Kubota, Jesús Cárdenas Sánchez, Jin-Hyoung Kang, Li Zhang, Alexander N. Fleishman, Joseph K. Park, Vera Hirsh, Konstantinos N. Syrigos, Carlos H. Barrios, Gary Thomas, David H. Henry, Cisio De Oliveira Brandao, Tilman Steinmetz, Dianne Tomita, Pere Gascón, Martin Šmakal, Rajnish Nagarkar, David Gordon

Publikováno v: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 15(2)

This study evaluated noninferiority of darbepoetin alfa versus placebo for overall survival (OS) and progression-free survival (PFS) in anemic patients with NSCLC treated to a 12.0-g/dL hemoglobin (Hb) ceiling.Adults with stage IV NSCLC expected to r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1e6825173ea32d5a6e5042671f9d1e4
https://pubmed.ncbi.nlm.nih.gov/32127181

Zobrazit plný text záznamu

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer

Publikováno v: Annals of Oncology. 25:1346-1355

Background: The Panitumumab Randomized trial In combination with chemotherapy for Metastatic colorectal cancer to determine Efficacy (PRIME) demonstrated that panitumumab-FOLFOX4 significantly improved progression-free survival (PFS) versus FOLFOX4 a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d92661d32bb3005fcdc5670043f53ff1
https://doi.org/10.1093/annonc/mdu141

Zobrazit plný text záznamu

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

Publikováno v: New England Journal of Medicine, Vol. 369, no.11, p. 1023-1034 (2013)

Patients with metastatic colorectal cancer that harbors KRAS mutations in exon 2 do not benefit from anti-epidermal growth factor receptor (EGFR) therapy. Other activating RAS mutations may also be negative predictive biomarkers for anti-EGFR therapy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca33096bb85a2552a91ba52866c33275
https://doi.org/10.1056/nejmoa1305275

Zobrazit plný text záznamu

Phase I/II Study of Pemetrexed With or Without ABT-751 in Advanced or Metastatic Non–Small-Cell Lung Cancer

Autor: Stanislav Spelda, Andrew Coates, Barry L. Dowell, Andrew Krivoshik, Jane Qian, Peter Ansell, Xiangdong Zhou, Gary S. Gordon, Rajendra S. Pradhan, Ann M. Mauer, Martin Šmakal, Evelyn McKeegan, Rosalyn A. Juergens, Charles M. Rudin, Michael S. Wertheim

Publikováno v: Journal of Clinical Oncology. 29:1075-1082

Purpose ABT-751 is an antimitotic and vascular disrupting agent with potent preclinical anticancer activity. We conducted a phase I and randomized double-blind phase II study of pemetrexed with ABT-751 or placebo in patients with recurrent advanced o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92882bc9bc37b39ddf5c47974e8889d2
https://doi.org/10.1200/jco.2010.32.5944

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání